DE10113876A1 - Quantitative diagnostische Analyse der Hypertonie - Google Patents

Quantitative diagnostische Analyse der Hypertonie

Info

Publication number
DE10113876A1
DE10113876A1 DE10113876A DE10113876A DE10113876A1 DE 10113876 A1 DE10113876 A1 DE 10113876A1 DE 10113876 A DE10113876 A DE 10113876A DE 10113876 A DE10113876 A DE 10113876A DE 10113876 A1 DE10113876 A1 DE 10113876A1
Authority
DE
Germany
Prior art keywords
hypertension
overexpression
blood pressure
quantitative diagnosis
modification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10113876A
Other languages
German (de)
English (en)
Inventor
Florian Lang
Andreas Busjahn
Friedrich C Luft
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LANG, FLORIAN, PROF. DR.MED., 72076 TUEBINGEN, DE
Original Assignee
EBERHARD KARLS UNI MEDIZINISCH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EBERHARD KARLS UNI MEDIZINISCH filed Critical EBERHARD KARLS UNI MEDIZINISCH
Priority to DE10113876A priority Critical patent/DE10113876A1/de
Priority to AU2002244751A priority patent/AU2002244751B2/en
Priority to DE50207305T priority patent/DE50207305D1/de
Priority to EP02712954A priority patent/EP1390531B1/de
Priority to RU2003130071/15A priority patent/RU2287160C2/ru
Priority to MXPA03008522A priority patent/MXPA03008522A/es
Priority to HU0303491A priority patent/HUP0303491A3/hu
Priority to HK04106088.6A priority patent/HK1063338B/xx
Priority to CA2441314A priority patent/CA2441314C/en
Priority to DK02712954T priority patent/DK1390531T3/da
Priority to PCT/EP2002/003180 priority patent/WO2002074987A2/de
Priority to US10/472,622 priority patent/US20060127892A1/en
Priority to JP2002574375A priority patent/JP2004528032A/ja
Priority to ES02712954T priority patent/ES2266463T3/es
Priority to PT02712954T priority patent/PT1390531E/pt
Priority to AT02712954T priority patent/ATE331043T1/de
Priority to CNB028086481A priority patent/CN1306040C/zh
Priority to PL02364387A priority patent/PL364387A1/xx
Publication of DE10113876A1 publication Critical patent/DE10113876A1/de
Priority to CY20061101052T priority patent/CY1105566T1/el
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
DE10113876A 2001-03-21 2001-03-21 Quantitative diagnostische Analyse der Hypertonie Withdrawn DE10113876A1 (de)

Priority Applications (19)

Application Number Priority Date Filing Date Title
DE10113876A DE10113876A1 (de) 2001-03-21 2001-03-21 Quantitative diagnostische Analyse der Hypertonie
DK02712954T DK1390531T3 (da) 2001-03-21 2002-03-21 Kvantitativ diagnostisk analyse af prædispositionen for hypertoni
PCT/EP2002/003180 WO2002074987A2 (de) 2001-03-21 2002-03-21 Quantitative diagnostische analyse der hypertonie
EP02712954A EP1390531B1 (de) 2001-03-21 2002-03-21 Quantitative diagnostische analyse der prädisposition für hypertonie
RU2003130071/15A RU2287160C2 (ru) 2001-03-21 2002-03-21 Количественный диагностический анализ гипертензии
MXPA03008522A MXPA03008522A (es) 2001-03-21 2002-03-21 Analisis diagnostico cuantitativo de la hipertension.
HU0303491A HUP0303491A3 (en) 2001-03-21 2002-03-21 Quantitative diagnostic analysis of hypertonia
HK04106088.6A HK1063338B (zh) 2001-03-21 2002-03-21 高血压的定量诊断分析
CA2441314A CA2441314C (en) 2001-03-21 2002-03-21 Quantitative diagnostic analysis of hypertension
AU2002244751A AU2002244751B2 (en) 2001-03-21 2002-03-21 Quantitative diagnostic analysis of hypertonia
DE50207305T DE50207305D1 (de) 2001-03-21 2002-03-21 Quantitative diagnostische analyse der prädisposition für hypertonie
US10/472,622 US20060127892A1 (en) 2001-03-21 2002-03-21 Quantitative diagnostic analysis of hypertonia
JP2002574375A JP2004528032A (ja) 2001-03-21 2002-03-21 高血圧症の定量的な診断分析
ES02712954T ES2266463T3 (es) 2001-03-21 2002-03-21 Analisis diagnostico cuantitativo de la hipertension.
PT02712954T PT1390531E (pt) 2001-03-21 2002-03-21 Analise de diagnostico quantitativa da hipertonia
AT02712954T ATE331043T1 (de) 2001-03-21 2002-03-21 Quantitative diagnostische analyse der prädisposition für hypertonie
CNB028086481A CN1306040C (zh) 2001-03-21 2002-03-21 高血压的定量诊断分析
PL02364387A PL364387A1 (en) 2001-03-21 2002-03-21 Quantitative diagnostic analysis of hypertonia
CY20061101052T CY1105566T1 (el) 2001-03-21 2006-07-28 Ποσοτικη διαγνωστικη αναλυση της προδιαθεσης για υπερταση

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10113876A DE10113876A1 (de) 2001-03-21 2001-03-21 Quantitative diagnostische Analyse der Hypertonie

Publications (1)

Publication Number Publication Date
DE10113876A1 true DE10113876A1 (de) 2002-09-26

Family

ID=7678460

Family Applications (2)

Application Number Title Priority Date Filing Date
DE10113876A Withdrawn DE10113876A1 (de) 2001-03-21 2001-03-21 Quantitative diagnostische Analyse der Hypertonie
DE50207305T Expired - Lifetime DE50207305D1 (de) 2001-03-21 2002-03-21 Quantitative diagnostische analyse der prädisposition für hypertonie

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE50207305T Expired - Lifetime DE50207305D1 (de) 2001-03-21 2002-03-21 Quantitative diagnostische analyse der prädisposition für hypertonie

Country Status (17)

Country Link
US (1) US20060127892A1 (enExample)
EP (1) EP1390531B1 (enExample)
JP (1) JP2004528032A (enExample)
CN (1) CN1306040C (enExample)
AT (1) ATE331043T1 (enExample)
AU (1) AU2002244751B2 (enExample)
CA (1) CA2441314C (enExample)
CY (1) CY1105566T1 (enExample)
DE (2) DE10113876A1 (enExample)
DK (1) DK1390531T3 (enExample)
ES (1) ES2266463T3 (enExample)
HU (1) HUP0303491A3 (enExample)
MX (1) MXPA03008522A (enExample)
PL (1) PL364387A1 (enExample)
PT (1) PT1390531E (enExample)
RU (1) RU2287160C2 (enExample)
WO (1) WO2002074987A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004070057A3 (de) * 2003-02-07 2004-11-25 Florian Lang Verwendung eines neuen polymorphismus im hsgk1-gen zur diagnose der hypertonie und verwendung der sgk-genfamilie zur diagnose und therapie des long-q/t-syndroms
RU2261442C2 (ru) * 2003-12-09 2005-09-27 Государственное образовательное учреждение высшего профессионального образования "Нижегородская Государственная Медицинская академия" МЗ РФ (ГОУ ВПО НижГМА) Способ диагностики артериальной гипертензии
WO2007025792A1 (de) * 2005-09-02 2007-03-08 Florian Lang Verfahren zur diagnose von hypertonie

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1455815A4 (en) * 2001-12-19 2006-11-02 Millennium Pharm Inc MEMBERS OF THE DIACYLGLYCEROL-ACYLTRANSFERASES FAMILY 2 (DGAT2) AND USES THEREOF
US6830911B2 (en) * 2002-02-08 2004-12-14 Applera Corporation Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2004079003A1 (de) * 2003-03-03 2004-09-16 Florian Lang Sgk1 als diagnostisches und therapeutisches target
DE10346913A1 (de) 2003-10-09 2005-05-04 Merck Patent Gmbh Acylhydrazonderivate
CN102654893A (zh) * 2011-03-04 2012-09-05 苏州卫生职业技术学院 分析高尿酸血症和高血压患病率关系的方法
WO2023114714A1 (en) * 2021-12-14 2023-06-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Sgk1 inhibitory compositions and methods

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19917990A1 (de) * 1999-04-20 2000-11-02 Florian Lang Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004070057A3 (de) * 2003-02-07 2004-11-25 Florian Lang Verwendung eines neuen polymorphismus im hsgk1-gen zur diagnose der hypertonie und verwendung der sgk-genfamilie zur diagnose und therapie des long-q/t-syndroms
RU2261442C2 (ru) * 2003-12-09 2005-09-27 Государственное образовательное учреждение высшего профессионального образования "Нижегородская Государственная Медицинская академия" МЗ РФ (ГОУ ВПО НижГМА) Способ диагностики артериальной гипертензии
WO2007025792A1 (de) * 2005-09-02 2007-03-08 Florian Lang Verfahren zur diagnose von hypertonie

Also Published As

Publication number Publication date
CA2441314A1 (en) 2002-09-26
US20060127892A1 (en) 2006-06-15
RU2003130071A (ru) 2005-04-10
HUP0303491A2 (hu) 2004-08-30
HUP0303491A3 (en) 2005-12-28
EP1390531A2 (de) 2004-02-25
WO2002074987A3 (de) 2003-12-04
CA2441314C (en) 2011-11-08
EP1390531B1 (de) 2006-06-21
WO2002074987A2 (de) 2002-09-26
AU2002244751C1 (en) 2002-10-03
PT1390531E (pt) 2006-09-29
AU2002244751B2 (en) 2007-01-11
ATE331043T1 (de) 2006-07-15
PL364387A1 (en) 2004-12-13
MXPA03008522A (es) 2005-03-07
DE50207305D1 (de) 2006-08-03
RU2287160C2 (ru) 2006-11-10
CN1306040C (zh) 2007-03-21
JP2004528032A (ja) 2004-09-16
ES2266463T3 (es) 2007-03-01
HK1063338A1 (en) 2004-12-24
DK1390531T3 (da) 2006-10-23
CY1105566T1 (el) 2010-07-28
CN1503848A (zh) 2004-06-09

Similar Documents

Publication Publication Date Title
Araujo et al. Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease
Flynn et al. Loss of high‐affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: implications for the failure of cholinergic replacement therapies
Havoundjian et al. The permeability of gamma-aminobutyric acid-gated chloride channels is described by the binding of a" cage" convulsant, t-butylbicyclophosphoro [35S] thionate.
EP0590551B1 (de) Neue therapeutische Verwendungen von Phthalazinon-Derivaten
Shimohama et al. Changes in β‐adrenergic receptor subtypes in Alzheimer‐type dementia
Nayler et al. Effect of ischaemia on cardiac contractility and calcium exchangeability
Feldblum et al. Quinolinic‐phosphoribosyl transferase activity is decreased in epileptic human brain tissue
Pol et al. Comparison of antiproliferative effects of experimental and established antipsoriatic drugs on human kerationocytes, using a simple 96-well-plate assay
Profita et al. Acetylcholine leads to signal transducer and activator of transcription 1 (STAT-1) mediated oxidative/nitrosative stress in human bronchial epithelial cell line
Vohanka et al. A mutation in the X-linked Emery–Dreifuss muscular dystrophy gene in a patient affected with conduction cardiomyopathy
EP1390531B1 (de) Quantitative diagnostische analyse der prädisposition für hypertonie
DE69927846T2 (de) Verfahren für die feststellung von asthma suszeptibilität
DE10305213A1 (de) Verwendung eines neuen Polymorphismus im hsgk1-Gen zur Diagnose der Hypertonie und Verwendung der sgk-Genfamilie zur Diagnose und Therapie des Long-Q/T-Syndroms
Murdocca et al. Mitochondrial dysfunction in mandibular hypoplasia, deafness and progeroid features with concomitant lipodystrophy (MDPL) patients
Brusov et al. Does platelet serotonin receptor supersensitivity accompany endogenous depression?
DE602004013431T2 (de) Identifikation von therapeutische verbindungen.
DE10305212A1 (de) Verwendung der sgk-Genfamilie zur Diagnose und zur Therapie von Katarakt und Glaukom
DE10225844A1 (de) sgk und nedd als diagnostische und therapeutische targets
DE69916672T2 (de) Androsteron-Derivate, deren Verwendung zur Unterdrückung der Bindung des Aktivatorproteins AP-1 an die DNA wie der Vermehrung der glatten Muskelzellen der Atemwege
Printemps et al. Role of cardiac IKs current in repolarization reserve process during late sodium current (INaL) activation
Giacobini Nicotinic cholinergic receptors in human brain: effects of aging and Alzheimer
Gao et al. Age-related decline in beta adrenergic and adenosine A1 receptor function in the heart are attenuated by dietary restriction
EP0907885B1 (de) Verfahren zum vergleichenden screenen von substanzen mit pharmakologischer wirkung
Blomstrand et al. Effects of Unilateral Warm and Cold Water Irrigation in the Outer Ear of Rabrits on Isolated Nerve Cells from the Lateral Vestibular Nucleus and Cerebellum
DE3153300C2 (de) Verfahren zur quantitativen Bestimmung von Encainid

Legal Events

Date Code Title Description
8127 New person/name/address of the applicant

Owner name: LANG, FLORIAN, PROF. DR.MED., 72076 TUEBINGEN, DE

8130 Withdrawal